pan-KRAS molecular glue

pan-KRAS molecular glue is a preclinical therapeutic program being developed by Eilean Therapeutics Australia for the treatment of solid tumors. The program utilizes molecular glue pharmacology to target the KRAS protein across a broad range of mutations (pan-KRAS), rather than being restricted to a single allele like G12C. By acting as a molecular glue, the compound is designed to facilitate or stabilize a novel interaction between KRAS and a third-party protein, such as an E3 ubiquitin ligase or a chaperone, leading to the modulation or degradation of KRAS and the subsequent inhibition of oncogenic signaling pathways. This approach aims to provide a more comprehensive therapeutic option for patients with KRAS-driven cancers that are not addressed by current allele-specific inhibitors.